RXRX vs SCHD
Recursion Pharmaceuticals Inc (RXRX) versus SCHD (SCHD) — a side-by-side from cached financials, not a winner call.
Recursion Pharmaceuticals Inc (RXRX) is a biotechnology company listed on NASDAQ.
SCHD (SCHD) common stock.
Latest reported RXRX revenue for 2024-12-31 was $58.8M. Net income was -$463.7M. Revenue was up 32.0% from 2023-12-31 to 2024-12-31. RXRX currently screens at market cap $1.75B.
SCHD does not have a complete income-statement cache yet.
RXRX currently screens at market cap $1.75B. SCHD currently screens at market cap $0.
Not investment advice. Open the RXRX and SCHD stock pages for the full models.
Not investment advice.